Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Low T2 Obese Asthma
NCT04108377Phase 1Terminated
- Sponsor
- University of California, Davis
- Start
- Jan 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing Roflumilast with Placebo (2 arms). Primary endpoint: Change in Beta 2 Agonist response from Baseline at 3 months. Started Jan 2019; status: terminated.
02
Drugs
roflumilast
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04108377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108377.